{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:43:55Z","timestamp":1784735035861,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.transproceed.2018.02.148","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T15:33:22Z","timestamp":1521387202000},"page":"2212-2217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Azacitidine for Relapse After Allogeneic Stem Cell Transplantation\u2014Single-Center Study"],"prefix":"10.1016","volume":"50","author":[{"given":"E.","family":"Karakulska-Prystupiuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Waszczuk-Gajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stefaniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dwilewicz-Trojaczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kulikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chmarzy\u0144ska-Mr\u00f3z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paluszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Boguradzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"J\u0119drzejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.02.148_bib1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21037\/sci.2016.11.04","article-title":"Hypomethyling agents after allogeneic blood stem cell transplantation","volume":"3","author":"Schroeder","year":"2016","journal-title":"Stem Cell Investig"},{"key":"10.1016\/j.transproceed.2018.02.148_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11899-013-0153-6","article-title":"Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"8","author":"Mawad","year":"2013","journal-title":"Curr Hemat Mail Rep"},{"key":"10.1016\/j.transproceed.2018.02.148_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-015-0208-3","article-title":"Model based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome","volume":"8","author":"Han","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.transproceed.2018.02.148_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bjh.13248","article-title":"Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia","volume":"169","author":"Oshikawa","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transproceed.2018.02.148_bib5","series-title":"Post-remission consolidation after allogeneic hematopoietic cell transplantation: fact or fiction","first-page":"8","author":"Majhail","year":"2012"},{"key":"10.1016\/j.transproceed.2018.02.148_bib6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2018.02.148_bib7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3324\/haematol.2014.114611","article-title":"Post-remission therapy for acute myeloid leukemia","volume":"99","author":"Schlenk","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.transproceed.2018.02.148_bib8","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"The main factors associated with better survival after second allo-HSCT are low disease burden and longer interval between the transplantations","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1016\/j.transproceed.2018.02.148_bib9","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transproceed.2018.02.148_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbmt.2013.11.017","article-title":"Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation","volume":"20","author":"Hourigan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2018.02.148_bib11","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.bbmt.2011.10.028","article-title":"Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies","volume":"18","author":"Bacher","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2018.02.148_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbmt.2015.07.037","article-title":"Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies","volume":"22","author":"Guieze","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2018.02.148_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA Trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2018.02.148_bib14","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V128.22.1162.1162","article-title":"Prospective phase II study of prohylactic azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high risk acute myeloid leukemia and myelodysplastic syndrome","volume":"128","author":"Guillaume","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2018.02.148_bib15","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1002\/cncr.24661","article-title":"Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities","volume":"115","author":"Ravandi","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.transproceed.2018.02.148_bib16","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","article-title":"Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"13","author":"Mielcarek","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2018.02.148_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HST; results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.transproceed.2018.02.148_bib18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocytye infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.transproceed.2018.02.148_bib19","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.transproceed.2018.02.148_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014a retrospective multicenter analysis from German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2018.02.148_bib21","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"De Lima","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.transproceed.2018.02.148_bib22","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with acute myeloid leukemia (AML)","volume":"119","author":"Schroeder","year":"2012","journal-title":"Blood"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518303361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518303361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T02:01:07Z","timestamp":1570932067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134518303361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0041134518303361"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.02.148","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azacitidine for Relapse After Allogeneic Stem Cell Transplantation\u2014Single-Center Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.02.148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}